Eli Lilly has scored a major victory in its battle for the US diabetes drug market after a trial showed its Trulicity cut risk of cardiovascular events, even in patients who had no prior history ...

Eli Lilly and Company LLY reported first-quarter 2025 adjusted earnings per share (“EPS”) of $3.34, which missed the Zacks Consensus Estimate of $3.52 per share. Earnings rose 29% year over year.

In 2025, Lilly also expects an unfavorable impact from foreign exchange rates on the top line. Sales of Trulicity are likely to have been hurt by competitive dynamics and lower realized prices in ...

Lilly’s tirzepatide medicines face strong competition from Novo Nordisk’s NVO GLP-drug semaglutide, which is approved as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes ...